GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘The Perspectives 2026’: An event for Malta’s IT decision-makers
BMIT’s upcoming ‘Perspectives 2026’ conference on April 14th brings together industry leaders to tackle challenges head-on and help decision-makers prepare ...
‘You built things that lasted’– Ivo Camilleri thanks teams as he exits BOV after 39 years
In a reflective message, Ivo Camilleri thanked all the people he worked with throughout the years.
Jesmond Fenech takes the helm at PayInsight
He will take on a dual CEO role as he continues to lead SpeedyDD
Malta’s ATTO lobbying for fairer EU transport rules for islands
Joseph Bugeja says the Combined Transport Directive shouldn't penalise island member states.
